wondering whether a different combo trial could be run in R/R AML so pricing isn’t eroded.
I don’t know much about how the price is determined, so based on the triangle report favouring a cardio protect + anti cancer effect.
thinking outside the box, to achieve this could Race do a 3 in 1 combo trial. Here is my thoughts:
R/R AML 3-in-1 #Decatabine + Venetoclax + Bisantrene
Bisantrene synergises with Decitabine
Bisantrene synergises with Venetoclax
Decitabine promotes FTO expression
Venetoclax is cardiotoxic
R/R AML overexpresses FTO
This supports Cardio protect, anti cancer and FTO all in one. Anything I’m missing why this would not work be a good idea scientifically or commercially?
How long would it take to check the combo invitro for synergy and cardio protect?
- Forums
- ASX - By Stock
- RAC
- Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells
Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells, page-194
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.76 |
Change
0.055(3.24%) |
Mkt cap ! $296.3M |
Open | High | Low | Value | Volume |
$1.74 | $1.82 | $1.72 | $207.8K | 119.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3756 | $1.76 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.76 | 4011 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3761 | 1.755 |
2 | 1300 | 1.725 |
2 | 2387 | 1.720 |
1 | 1087 | 1.715 |
2 | 1977 | 1.710 |
Price($) | Vol. | No. |
---|---|---|
1.760 | 4011 | 2 |
1.770 | 1200 | 1 |
1.795 | 6045 | 1 |
1.800 | 2500 | 1 |
1.810 | 2400 | 1 |
Last trade - 15.18pm 08/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |